INT9884

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1986
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 41
Total Number 42
Disease Relevance 21.75
Pain Relevance 3.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD79A)
Anatomy Link Frequency
plasma cells 2
antibody secreting cells 2
eosinophils 2
respiratory tract 2
glands 2
CD79A (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 271 100.00 Very High Very High Very High
endometriosis 168 100.00 Very High Very High Very High
Opioid 2 99.76 Very High Very High Very High
Inflammation 383 99.36 Very High Very High Very High
dexamethasone 385 97.14 Very High Very High Very High
peptic ulcer disease 7 92.64 High High
nud 31 87.80 High High
spinal inflammation 1 87.64 High High
spastic colon 47 86.52 High High
Arthritis 5 85.84 High High
Disease Link Frequency Relevance Heat
Disease 371 100.00 Very High Very High Very High
Endometriosis 224 100.00 Very High Very High Very High
Renal Disease 33 100.00 Very High Very High Very High
Iga Nephropathy 1 100.00 Very High Very High Very High
Gastritis 25 99.68 Very High Very High Very High
Stress 127 99.56 Very High Very High Very High
INFLAMMATION 417 99.36 Very High Very High Very High
Lung Cancer 29 99.30 Very High Very High Very High
Emphysema 1 99.04 Very High Very High Very High
Immunization 367 98.94 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
IgA-secreting plasmocytes were also present (about 23% of the inflammatory infiltrate).
Localization (secreting) of IgA associated with inflammation
1) Confidence 0.78 Published 1986 Journal Presse Med Section Abstract Doc Link 2940571 Disease Relevance 0.26 Pain Relevance 0.12
Secretory IgA plays a major role in preventing antigen uptake, both of infectious and non-infectious types.
Localization (Secretory) of IgA
2) Confidence 0.73 Published 1992 Journal Agents Actions Section Abstract Doc Link 1442333 Disease Relevance 0.14 Pain Relevance 0.09
PATIENTS AND METHODS: We here report a case of devastating extramedullary relapse of IgA/lambdaMM (stage IA) treated at diagnosis with a dexamethasone, adriamycin, vincristine (DAV) regimen followed by high-dose therapy and autologous stem cell transplantation (ASCT), achieving a partial remission.
Localization (relapse) of IgA in stem cell
3) Confidence 0.73 Published 2009 Journal Onkologie Section Body Doc Link 19295251 Disease Relevance 0.09 Pain Relevance 0
Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis.
Localization (secretory) of IgA associated with immunization and gastritis
4) Confidence 0.73 Published 1995 Journal J. Infect. Dis. Section Title Doc Link 7797906 Disease Relevance 0.57 Pain Relevance 0.09
Protection correlated with the level of secretory IgA antibodies against urease.
Localization (secretory) of IgA
5) Confidence 0.73 Published 1995 Journal J. Infect. Dis. Section Abstract Doc Link 7797906 Disease Relevance 0.47 Pain Relevance 0.08
2-microglobulin status.2,3 Moreover, the combination of lenalidomide plus dexamethasone is effective at prolonging OS irrespective of prior thalidomide use or the number of previous therapies; OS is also improved in patients with IgA disease at baseline and in patients with an ECOG performance status >0.2,3,101,102 In the relapsed or refractory setting, lenalidomide is emerging as a suitable partner for bortezomib, with nonoverlapping toxicities and a high rate of response.62,119
Localization (disease) of IgA associated with disease and dexamethasone
6) Confidence 0.73 Published 2010 Journal Core evidence Section Body Doc Link PMC2899783 Disease Relevance 0.24 Pain Relevance 0.25
We demonstrated that the autoantibodies detected by ANA were not of the IgA isotype, so it is possible that the IgA antibodies are simply elicited by nonspecific chronic inflammatory processes in these individuals.
Neg (not) Localization (were) of IgA isotype associated with inflammation
7) Confidence 0.67 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1253705 Disease Relevance 0.74 Pain Relevance 0.22
Peptides that modulate such intestinal immune functions as secretory IgA production and cytokine secretion, and opioid peptides regulating intestinal motility are also included in this group.
Localization (secretion) of IgA associated with opioid and cytokine
8) Confidence 0.45 Published 2007 Journal Curr. Pharm. Des. Section Abstract Doc Link 17430188 Disease Relevance 0.44 Pain Relevance 0.33
IgA2 and IgG3 were the predominant IgA and IgG subclasses in luminal secretions in 19/20 (95%) and 20/20 (100%) subjects, respectively.
Localization (secretions) of IgA
9) Confidence 0.33 Published 1998 Journal Dig. Dis. Sci. Section Abstract Doc Link 9512143 Disease Relevance 0.26 Pain Relevance 0.13
Secretory IgA has crucial roles to bathe tooth surfaces and to inhibit colonization by S. mutans.14 Since EBV periodontal presence is associated with an elevated occurrence of periodontopathic anaerobic bacteria11 the balance between IgA and EBV level in saliva might have some importance in etiopathogenesis of severe caries patterns.
Localization (Secretory) of IgA in saliva associated with epstein-barr virus
10) Confidence 0.29 Published 2010 Journal European Journal of Dentistry Section Body Doc Link PMC2798787 Disease Relevance 1.03 Pain Relevance 0.08
Secretory IgA coats the lumen or interior surface of small intestine and prevents any microbial pathogens or viruses penetrating the epithelial layer and passing into the other organs [29,47].
Localization (Secretory) of IgA in small intestine
11) Confidence 0.28 Published 2005 Journal BMC Nurs Section Body Doc Link PMC549542 Disease Relevance 0.50 Pain Relevance 0.23
Secretory immunoglobulin A (S-IgA),
Localization (Secretory) of IgA
12) Confidence 0.25 Published 2005 Journal BMC Nurs Section Body Doc Link PMC549542 Disease Relevance 0.88 Pain Relevance 0.16
IgA is actively transported in its secretory form, S-IgA, across the epithelial surfaces of the respiratory tract and neutralizes virus by binding to its surface proteins.
Localization (transported) of IgA in respiratory tract
13) Confidence 0.19 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2695195 Disease Relevance 1.46 Pain Relevance 0.04
IgA is actively transported in its secretory form, S-IgA, across the epithelial surfaces of the respiratory tract and neutralizes virus by binding to its surface proteins.
Localization (transported) of S-IgA in respiratory tract
14) Confidence 0.19 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2695195 Disease Relevance 1.46 Pain Relevance 0.04
For subjects receiving 108 CFU: After first immunization mean peak IgG titer to LT 2625 (peak fold increase 2.5), mean peak IgA ASC response to LT 0, mean peak IgG titer to LPS 2073 (15.4), mean peak IgA ASC response to LPS 121.
Localization (response) of IgA associated with immunization
15) Confidence 0.19 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.34 Pain Relevance 0
For the responses to ETEC LT: Amongst the 36 subjects recruited, 67% demonstrated an IgG or IgA immune response against ETEC LT measured either by ELISPOT or ELISA.
Localization (response) of IgA
16) Confidence 0.19 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.06 Pain Relevance 0
After second immunization mean peak IgG titer to LT 3056 (peak fold increase 3.5), mean peak IgA ASC response to LT 0.73, mean peak IgG titer to LPS 1680 (7.9), mean peak IgA ASC response to LPS 13.
Localization (response) of IgA associated with immunization
17) Confidence 0.19 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.34 Pain Relevance 0
For subjects receiving 109 CFU: After first immunization mean peak IgG titer to LT 4184 (peak fold increase 4.2), mean peak IgA ASC response to LT 8.29, mean peak IgG titer to LPS 3724 (13.1), mean peak IgA ASC response to LPS 158.
Localization (response) of IgA associated with immunization
18) Confidence 0.19 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.36 Pain Relevance 0
After second immunization mean peak IgG titer to LT 3056 (peak fold increase 3.5), mean peak IgA ASC response to LT 0.73, mean peak IgG titer to LPS 1680 (7.9), mean peak IgA ASC response to LPS 13.
Localization (response) of IgA associated with immunization
19) Confidence 0.19 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.38 Pain Relevance 0
For subjects receiving 108 CFU: After first immunization mean peak IgG titer to LT 2625 (peak fold increase 2.5), mean peak IgA ASC response to LT 0, mean peak IgG titer to LPS 2073 (15.4), mean peak IgA ASC response to LPS 121.
Localization (response) of IgA associated with immunization
20) Confidence 0.19 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.32 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox